21:29 , Jun 1, 2018 |  BioCentury  |  Finance

CalPERS goes direct

The strong performance of direct life science investments made by some sovereign wealth or pension funds could be part of the rationale for CalPERS’s plan to launch its own direct investment fund that could funnel...
21:38 , Apr 13, 2018 |  BioCentury  |  Finance

Add-venture

A confluence of larger funds, greater interest from non-traditional investors and Asian firms, and an increased inclination to raise larger, often tranched rounds helped U.S. biotech raise nearly $4.1 billion in venture money in 1Q18,...
02:13 , Dec 14, 2017 |  BC Week In Review  |  Financial News

Denali raises $250M in IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were Goldman Sachs, Morgan Stanley, JPMorgan and Evercore ISI. The price is at the midpoint...
16:41 , Dec 8, 2017 |  BC Extra  |  Financial News

Denali climbs after $250M IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) jumped $3.45 (19%) to $21.45 in its first day of trading Friday after it raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were...
22:09 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Codiak raises $76.5M in series C

Exosome therapeutics company Codiak BioSciences Inc. (Cambridge, Mass.) raised $76.5 million in an untranched series C round. Existing investors Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners, Fidelity and Flagship Pioneering were joined by...
18:12 , Dec 1, 2017 |  BioCentury  |  Finance

Blue skies for Codiak

EcoR1 opted to join Codiak BioSciences Inc.’s series C round based on the track record of the biotech’s team and the broad utility of its exosome therapeutics platform. The deal aims to get the company...
12:07 , Nov 29, 2017 |  BC Extra  |  Financial News

Codiak raises $76.5M series C

Exosome therapeutics company Codiak BioSciences Inc. (Cambridge, Mass.) raised $76.5 million in an untranched series C round. Existing investors Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners, Fidelity and Flagship Pioneering were joined by...
19:14 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
00:27 , Nov 15, 2017 |  BC Extra  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
18:01 , Oct 20, 2017 |  BC Week In Review  |  Company News

Vir unveils series of deals, additional funding

On Oct. 18, Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round...